The award is a significant positive step toward developing treatment for a currently incurable condition that affects approximately 1.5m Americans every year, killing 50,000 annually.
The Centers for Disease Control reports an estimated 5.3 m people live with permanent TBI-related disability in the US.
More than 460,000 military service members have been diagnosed with TBI since 2000.
Preliminary results from a prior Phase I/IIa, 24-patient study sponsored by Hope Biosciences at UTHealth (NCT04063215) were presented in May during the Cellular Therapies and Transfusion Medicine in Trauma and Critical Care (CTTACC) 2023 Conference in Scottsdale, Arizona.
Repeated intravenous administration of HB-adMSCs demonstrated the potential of reducing chronic neuroinflammation.
This award constitutes the Department of Defense's first support of UTHealth Houston's and Hope Biosciences' collaboration.
The anticipated multi-center Phase II study is set to begin enrollment in September, pending approval by UTHealth Houston's Institutional Review Board.
Headquartered in Sugar Land, Texas and now in its seventh year of operation, to date MSCs cultured at Hope Biosciences have been used in more than 35 FDA-authorized clinical studies covering a wide range of conditions including chronic injury, degenerative diseases and autoimmune diseases.
Merck's sotatercept gains priority review for PAH treatment
Antibe gains approval for otenaproxesul PK/PD study
Calliditas Therapeutics' setanaxib receives US FDA orphan drug designation
Everads Therapy signs license, collaboration and supply agreement with Kriya Therapeutics
IDEAYA Biosciences' IDE161 receives US FDA fast track designation
YS Biopharma enrols first subject in Phase three PIKA Rabies Vaccine clinical trial
Armata Pharmaceuticals doses first patient in Phase 2a of AP-SA02 diSArm study
Melt Pharmaceuticals enters exclusive agreement with Catalent for Zydis fast-dissolve tech
EXACT Therapeutics' ACTIVATE trial shows promise in enhancing chemotherapy efficacy
Sanofi granted Priority Review for EoE treatment in young children
Pierre Fabre Laboratories signs long-term collaboration with Vernalis (R&D)
BioArctic and Eisai secure approval for LEQEMBI infusion in Japan for Alzheimer's disease treatment